Genotyping of S‐mephenytoin 4′‐hydroxylation in an extended Japanese population

To assess the genotype pattern of S‐mephenytoin 4′‐hydroxylation in an extended Japanese population.

[1]  K. Chiba,et al.  Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes. , 1994, The Journal of pharmacology and experimental therapeutics.

[2]  K. Brøsen,et al.  Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms , 1993, Therapeutic drug monitoring.

[3]  T. Ishizaki,et al.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese , 1989, Clinical pharmacology and therapeutics.

[4]  R. Branch,et al.  Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquin, and mephenytoin , 1990, Clinical pharmacology and therapeutics.

[5]  S. Kitareewan,et al.  Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. , 1994, Biochemistry.

[6]  D. Laurence,et al.  Clinical Pharmacology & Therapeutics , 1980, Palgrave Macmillan UK.

[7]  T. Ishizaki,et al.  S-MEPHENYTOIN PHARMACOGENETICS AND ITS CLINICAL IMPLICATIONS IN ASIAN ETHNIC POPULATIONS , 1994 .

[8]  D. Clauw,et al.  Pharmacogenetic characteristics of the eosinophilia‐myalgia syndrome , 1994, Clinical pharmacology and therapeutics.

[9]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[10]  T. Kamataki,et al.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.

[11]  J. Brockmöller,et al.  Assessment of Liver Metabolic Function , 1994, Clinical pharmacokinetics.

[12]  J. Goldstein,et al.  A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. , 1995, Pharmacogenetics.

[13]  Kaoru Kobayashi,et al.  The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes. , 1995, British journal of clinical pharmacology.

[14]  R. Branch,et al.  Genetic polymorphism of S-mephenytoin hydroxylation. , 1989, Pharmacology & therapeutics.

[15]  R. Branch,et al.  Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. , 1987, Cancer research.

[16]  J. Brockmöller,et al.  Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation. , 1995, Pharmacogenetics.

[17]  L. Bertilsson,et al.  Genetically variable metabolism of antidepressants and neuroleptic drugs in man. , 1993, Pharmacogenetics.

[18]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[19]  L. Bertilsson,et al.  Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype , 1989, Clinical pharmacology and therapeutics.

[20]  K. Chiba,et al.  Incidence of S‐mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics , 1992, Clinical pharmacology and therapeutics.

[21]  R. Branch,et al.  Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities , 1989, Clinical pharmacology and therapeutics.

[22]  J. Goldstein,et al.  Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.

[23]  L. Pickle,et al.  The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: A population study , 1995, Clinical pharmacology and therapeutics.

[24]  Yuan Zhang,et al.  Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. , 1992, Pharmacogenetics.

[25]  M. Ingelman-Sundberg,et al.  Phenotyping and genotyping of S‐mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe , 1995, Clinical pharmacology and therapeutics.

[26]  J. Hallas,et al.  The mephenytoin oxidation polymorphism is partially responsible for the N‐demethylation of imipramine , 1991, Clinical pharmacology and therapeutics.

[27]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.